Shares of NuCana plc (NASDAQ:NCNA – Get Free Report) traded down 6.5% on Thursday . The stock traded as low as $1.14 and last traded at $1.15. 118,431 shares changed hands during trading, an increase of 6% from the average session volume of 111,346 shares. The stock had previously closed at $1.23.
NuCana Stock Down 1.7 %
The firm has a 50 day moving average of $1.32 and a two-hundred day moving average of $2.62. The firm has a market capitalization of $2.99 million, a price-to-earnings ratio of -0.11 and a beta of 0.97.
Hedge Funds Weigh In On NuCana
A hedge fund recently bought a new stake in NuCana stock. Glass Jacobson Investment Advisors llc purchased a new stake in shares of NuCana plc (NASDAQ:NCNA – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned approximately 0.57% of NuCana at the end of the most recent quarter. Institutional investors own 44.00% of the company’s stock.
About NuCana
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Recommended Stories
- Five stocks we like better than NuCana
- Business Services Stocks Investing
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- How to Effectively Use the MarketBeat Ratings Screener
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.